190 related articles for article (PubMed ID: 21963455)
1. The novel trisubstituted pyran derivative D-142 has triple monoamine reuptake inhibitory activity and exerts potent antidepressant-like activity in rodents.
Dutta AK; Gopishetty B; Gogoi S; Ali S; Zhen J; Reith M
Eur J Pharmacol; 2011 Dec; 671(1-3):39-44. PubMed ID: 21963455
[TBL] [Abstract][Full Text] [Related]
2. D-161, a novel pyran-based triple monoamine transporter blocker: behavioral pharmacological evidence for antidepressant-like action.
Dutta AK; Ghosh B; Biswas S; Reith ME
Eur J Pharmacol; 2008 Jul; 589(1-3):73-9. PubMed ID: 18561912
[TBL] [Abstract][Full Text] [Related]
3. Structural exploration of (3S,6S)-6-benzhydryl-N-benzyltetrahydro-2H-pyran-3-amine analogues: identification of potent triple monoamine reuptake inhibitors as potential antidepressants.
Santra S; Gogoi S; Gopishetty B; Antonio T; Zhen J; Reith ME; Dutta AK
ChemMedChem; 2012 Dec; 7(12):2093-100. PubMed ID: 23060293
[TBL] [Abstract][Full Text] [Related]
4. Further structure-activity relationship studies on 4-((((3S,6S)-6-benzhydryltetrahydro-2H-pyran-3-yl)amino)methyl)phenol: identification of compounds with triple uptake inhibitory activity as potential antidepressant agents.
Gopishetty B; Hazeldine S; Santra S; Johnson M; Modi G; Ali S; Zhen J; Reith M; Dutta A
J Med Chem; 2011 Apr; 54(8):2924-32. PubMed ID: 21446715
[TBL] [Abstract][Full Text] [Related]
5. Flexible and biomimetic analogs of triple uptake inhibitor 4-((((3S,6S)-6-benzhydryltetrahydro-2H-pyran-3-yl)amino)methyl)phenol: Synthesis, biological characterization, and development of a pharmacophore model.
Sharma H; Santra S; Debnath J; Antonio T; Reith M; Dutta A
Bioorg Med Chem; 2014 Jan; 22(1):311-24. PubMed ID: 24315194
[TBL] [Abstract][Full Text] [Related]
6. Pharmacological and behavioral characterization of D-473, an orally active triple reuptake inhibitor targeting dopamine, serotonin and norepinephrine transporters.
Dutta AK; Santra S; Sharma H; Voshavar C; Xu L; Mabrouk O; Antonio T; Reith ME
PLoS One; 2014; 9(11):e113420. PubMed ID: 25427177
[TBL] [Abstract][Full Text] [Related]
7. The novel triple reuptake inhibitor JZAD-IV-22 exhibits an antidepressant pharmacological profile without locomotor stimulant or sensitization properties.
Caldarone BJ; Paterson NE; Zhou J; Brunner D; Kozikowski AP; Westphal KG; Korte-Bouws GA; Prins J; Korte SM; Olivier B; Ghavami A
J Pharmacol Exp Ther; 2010 Dec; 335(3):762-70. PubMed ID: 20864506
[TBL] [Abstract][Full Text] [Related]
8. Antidepressant-like actions of DOV 21,947: a "triple" reuptake inhibitor.
Skolnick P; Popik P; Janowsky A; Beer B; Lippa AS
Eur J Pharmacol; 2003 Feb; 461(2-3):99-104. PubMed ID: 12586204
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo characterization of PA01, a novel promising triple reuptake inhibitor.
Hou J; Xing Y; Zuo D; Wu Y; Tian J; Meng Q; Yang M
Physiol Behav; 2015 Jan; 138():141-9. PubMed ID: 25447484
[TBL] [Abstract][Full Text] [Related]
10. Antidepressant-like effects of novel triple reuptake inhibitors, PRC025 and PRC050.
Shaw AM; Boules M; Zhang Y; Williams K; Robinson J; Carlier PR; Richelson E
Eur J Pharmacol; 2007 Jan; 555(1):30-6. PubMed ID: 17109850
[TBL] [Abstract][Full Text] [Related]
11. Preclinical pharmacology of TP1, a novel potent triple reuptake inhibitor with antidepressant properties.
Tian JW; Jiang WL; Zhong Y; Meng Q; Gai Y; Zhu HB; Hou J; Xing Y; Li YX
Neuroscience; 2011 Nov; 196():124-30. PubMed ID: 21925241
[TBL] [Abstract][Full Text] [Related]
12. Development of potent dopamine-norepinephrine uptake inhibitors (DNRIs) based on a (2S,4R,5R)-2-benzhydryl-5-((4-methoxybenzyl)amino)tetrahydro-2H-pyran-4-ol molecular template.
Santra S; Sharma H; Vedachalam S; Antonio T; Reith M; Dutta A
Bioorg Med Chem; 2015 Feb; 23(4):821-8. PubMed ID: 25593099
[TBL] [Abstract][Full Text] [Related]
13. Antidepressant-like effect of scopoletin, a coumarin isolated from Polygala sabulosa (Polygalaceae) in mice: evidence for the involvement of monoaminergic systems.
Capra JC; Cunha MP; Machado DG; Zomkowski AD; Mendes BG; Santos AR; Pizzolatti MG; Rodrigues AL
Eur J Pharmacol; 2010 Sep; 643(2-3):232-8. PubMed ID: 20599906
[TBL] [Abstract][Full Text] [Related]
14. [Synthesis and antidepressant activities of aryl alkanol piperidine derivatives].
Zheng YY; Gao K; Weng ZJ; Li JQ
Yao Xue Xue Bao; 2010 Mar; 45(3):324-9. PubMed ID: 21351508
[TBL] [Abstract][Full Text] [Related]
15. Antidepressant-like pharmacological profile of a novel triple reuptake inhibitor, (1S,2S)-3-(methylamino)-2-(naphthalen-2-yl)-1-phenylpropan-1-ol (PRC200-SS).
Liang Y; Shaw AM; Boules M; Briody S; Robinson J; Oliveros A; Blazar E; Williams K; Zhang Y; Carlier PR; Richelson E
J Pharmacol Exp Ther; 2008 Nov; 327(2):573-83. PubMed ID: 18689611
[TBL] [Abstract][Full Text] [Related]
16. D-578, an orally active triple monoamine reuptake inhibitor, displays antidepressant and anti-PTSD like effects in rats.
Dutta AK; Santra S; Harutyunyan A; Das B; Lisieski MJ; Xu L; Antonio T; Reith MEA; Perrine SA
Eur J Pharmacol; 2019 Nov; 862():172632. PubMed ID: 31473161
[TBL] [Abstract][Full Text] [Related]
17. Antidepressant-like Effects of LPM580153, A Novel Potent Triple Reuptake Inhibitor.
Zhang F; Shao J; Tian J; Zhong Y; Ye L; Meng X; Liu Q; Wang H
Sci Rep; 2016 Apr; 6():24233. PubMed ID: 27052887
[TBL] [Abstract][Full Text] [Related]
18. Monoamine involvement in the antidepressant-like effect induced by P2 blockade.
Diniz CRAF; Rodrigues M; Casarotto PC; Pereira VS; Crestani CC; Joca SRL
Brain Res; 2017 Dec; 1676():19-27. PubMed ID: 28916441
[TBL] [Abstract][Full Text] [Related]
19. Antidepressant-like effects of 071031B, a novel serotonin and norepinephrine reuptake inhibitor.
Xue R; Jin ZL; Chen HX; Yuan L; He XH; Zhang YP; Meng YG; Xu JP; Zheng JQ; Zhong BH; Li YF; Zhang YZ
Eur Neuropsychopharmacol; 2013 Jul; 23(7):728-41. PubMed ID: 22748419
[TBL] [Abstract][Full Text] [Related]
20. The antidepressant-like pharmacological profile of Yuanzhi-1, a novel serotonin, norepinephrine and dopamine reuptake inhibitor.
Jin ZL; Gao N; Li XR; Tang Y; Xiong J; Chen HX; Xue R; Li YF
Eur Neuropsychopharmacol; 2015 Apr; 25(4):544-56. PubMed ID: 25638027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
